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ABSTRACT
The authors report here the case of a patient with severe
deficits in arousal and sustained attention, associated
with hemispatial neglect. These impairments were
secondary to acute disseminated encephalomyelitis, with
bilateral involvement of the medial nuclei and pulvinar of
the thalamus. Treatment with the noradrenergic agonist
guanfacine, previously used for attention deficits in
attention deficit/hyperactivity disorder and stroke, was
associated with a significant amelioration of both the
spatial and sustained attention impairments in neglect.
Guanfacine may prove to be a useful tool in the
treatment of disorders of attention associated with
neurological conditions.
Acute disseminated encephalomyelitis (ADEM) is
a relatively rare neuroinﬂammatory disorder asso-
ciated with multifocal lesions, frequently preceded
by a viral prodrome. It is usually a monophasic
illness, with many patients recovering well,
although up to half followed up long-term have
been reported to have persistent neurological deﬁ-
cits.1 MRI usually reveals asymmetrical subcortical
white-matter involvement. However, the deep
grey-matter nuclei, such as the thalamus and basal
ganglia, may also be affected.2
There are few studies documenting the cognitive
and neuropsychological sequelae of ADEM,3 4 with
most focussing onmotor disabilities. Here,we report
a patient with thalamic lesions secondary to ADEM,
causing persistent left-sided hemispatial neglect
(failure to attend to stimuli in contralesional space)
and difﬁculty sustaining attention. These deﬁcits
were subsequently ameliorated by administration of
the noradrenergic agonist guanfacine, a drug that has
been shown to have positive effects in children with
attention deﬁcit/hyperactivity disorder,5 as well as
sustained and spatial attention deﬁcits in some
patients with neglect secondary to stroke.6
CASE REPORT
A 38-year-old male presented with a right-sided
facial droop and hemiparesis following a 2-week
prodrome of headache, fever, cough and right
hemisensory symptoms. Soon after admission, he
developed toniceclonic seizures, necessitating
treatment with phenytoin, intubation and venti-
lation. MRI revealed patchy signal changes in the
thalamus, cerebellum, temporal and occipital lobes
bilaterally, while MR angiogram revealed normal
extra- and intracranial blood ﬂow. Cerebrospinal
ﬂuid examination, vasculitic blood screen and
transoesophageal echocardiogram were normal.
Electroencephalography demonstrated features
consistent with encephalopathy, and a diagnosis of
ADEM was made. He subsequently received two
courses of intravenous methylprednisolone, intra-
venous immunoglobulin, plasma exchange and
antibiotics. He was also anticoagulated for a deep
venous thrombosis and required surgical treatment
for an associated compartment syndrome.
The patient remained in intensive care, due to
persistent epileptiform activity, for 4 months,
when seizures were stabilised on a regimen of
levetiracetam 2 g, phenytoin 700 mg and prednis-
olone 30 mg. He was then transferred to a rehabili-
tation unit, at which time he had a tetraparesis,
with predominant left-sided weakness.
Neuropsychological testing also revealed signiﬁ-
cant cognitive impairments, including left-sided
neglect (with intact visual ﬁelds on confrontation),
reduced arousal and difﬁculty sustaining attention.
In addition, there were signiﬁcant impairments in
verbal memory (chance performance on the short
and easy Recognition Memory Test for verbal
material and low average performance on the
Wechsler Adult Intelligence ScaledRevised (WAIS-
R) Digit Span subtest) and naming (5/15 correct on
Graded Naming Test). There was also evidence of
dysfunction on tests of executive function
(concrete performance on Proverb Interpretation
and perseveration on Single Letter Reading and the
Similarities subtest of the WAIS-R). On the basis of
educational and occupational background, he was
estimated to have been functioning in at least the
superior range premorbidly and had therefore
suffered severe intellectual deterioration.
Admission for reassessment occurred 2 years
later, at which time anticonvulsant medication
consisted of levetiracetam 750 mg and gabapentin
300 mg both twice daily (the total daily dose of
levetiracetam was 1250 mg at 6 months’ follow-up,
with a further reduction to 1000 mg 10 months
later). Cranial nerve examination was normal,
except for a mild left-sided facial weakness. Exam-
ination of the limbs revealed a severe hemiparesis
with increased tone on the left and a pyramidal
distribution of weakness, worse distally. The limb
reﬂexes were all brisk with bilaterally extensor
plantar responses. There was severe left hemispatial
neglect and impairments in sustained attention and
arousal, with the patient spending 20 h a day in bed
due to drowsiness. A decision was taken to trial the
alpha-2-noradrenergic agonist guanfacine, with the
hypothesis that this might improve these cognitive
impairments.
ASSESSMENT MEASURES
MRI was repeated to determine the extent of lesions
(ﬁgure 1A). Two standard bedside neuropsychological
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tests were used to assess neglect, while a computerised task was
used to measure the deﬁcit in sustained attention. The neglect
tests used were line cancellation, in which subjects are
instructed to cancel all the lines they can ﬁnd (total 40)
distributed across an A4 sheet of paper and bisection of 17 cm
horizontal lines, where the mean deviation rightwards from
centre was taken from three attempts. The computerised task
which has been used previously7 was presented on a Dell Lati-
tude D820 laptop computer, and entailed the subject depressing
the central button on a response box (RB-530 Cedrus Corp.),
whenever an infrequently occurring black circle (8 mm diam-
eter) occurred. The circle remained on the screen for 1 s and was
presented on a grey background with interstimulus intervals of
1e7 s. 100 stimuli were presented over a total period of 8 min.
Responses quicker than 100 ms were classiﬁed as anticipa-
tions, and therefore as commission errors, as were responses
occurring more than 1600 ms after target onset. Perceptual
sensitivity, or d9, which is derived from signal detection theory8
and takes into account commission as well as omission errors,
was the behavioural outcome measure of this task and calcu-
lated according to the formula below:
d9 ¼ F1ðHÞ  F1ðFÞ
where H is the hit rate, and F is the false alarm rate. The higher
this value, the better the subject was at accurately detecting
targets.
These tests were performed on two consecutive days prior to
commencing guanfacine, as well as at several time points after
its introduction. The dose of guanfacine was titrated up slowly
over 3 days in the following increments: 0.5 mg, 1 mg and 2 mg
as single daily doses. The ﬁrst on-guanfacine testing session was
performed the day 2 mg was reached.
An additional testing session off-guanfacine was performed
2 months later (due to initial difﬁculty obtaining the drug
locally) at which point the patient had not received guanfacine
for 2 weeks. Three on-guanfacine testing sessions were
performed 6 months after the initial commencement of 2 mg of
guanfacine daily, and a ﬁnal session occurred a further
10 months later. Therefore, in total, the patient underwent three
testing sessions off and ﬁve on guanfacine. Testing was always
performed during the afternoon.
Guanfacine has previously been well tolerated in studies
investigating its efﬁcacy in children and adolescents with
attention deﬁcit/hyperactivity disorder; however, the most
commonly experienced side effects include drowsiness, sedation
and dizziness.5 9 The patient reported here did not experience
any side effects.
RESULTS
Figure 1A demonstrates the thalamic lesions on T2-weighted
MRI, along with performance on attention tests on and off
guanfacine. The thalamic lesions localise to the medial thalamic
nuclei (including the mediodorsal nucleus) and pulvinar on the
left and to the pulvinar on the right.10 Lesions of the right
pulvinar have previously been linked to the pathogenesis of
neglect,11 while the patient’s remaining small lesions (in the
cerebellum, temporal and occipital lobes) all lie outside areas
commonly associated with the syndrome, such as the inferior
parietal lobe, temporoparietal junction and inferior frontal
lobe.12 13
All three measures used to assess attention deﬁcits improved
on guanfacine. Permutation testing was used to investigate
whether these effects were statistically signiﬁcant. This estab-
lished procedure has speciﬁcally been used in single-case designs
Figure 1 Bilateral thalamic lesions
associated with hemispatial neglect and
impaired sustained attention, and
amelioration with guanfacine. (A)
Bilateral thalamic lesions as
demonstrated by T2-weighted MRI
scanning. The red arrow indicates one of
the left-sided lesions, involving the
medial thalamic nuclei, including the
medio-dorsal nucleus. There are also
smaller adjacent lesions in the pulvinar
(blue arrow). The yellow arrow indicates
the right-sided lesion, which is also in
the pulvinar. (B) Line bisection. The
rightward deviation on bisecting 17 cm
lines decreased significantly after
commencement of guanfacine
(deviation given in mm). (C) Line
cancellation. The total number of lines
cancelled by the patient increased on
2 mg of guanfacine. (D) Perceptual
sensitivity on the sustained attention
task improved significantly on
guanfacine treatment. Pre,
preguanfacine; Post 1, initial
assessment after commencement of
2 mg of guanfacine; Off, assessment at
2 months after guanfacine had been
ceased for 2 weeks; Post 2,
assessments at 6 months after initiation
of guanfacine; Post 3, assessment at
16 months after initiation of guanfacine.
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and works by considering all possible recombinations of the
data.14 The purpose of considering these recombinations or
permutations is to attempt to account for ﬂuctuations in
assessment scores which may occur over time, unrelated to the
effects of treatment.
First, the difference between the actual baseline and treatment
means is calculated. Then, the mean difference for every other
possible combination of data if the treatment had been intro-
duced at different time points in the data set is computed. In
other words, imagine that you were given the results without
knowing when the patient was on or off a drug. One could look
at all the different permutations of being on and off a drug and
calculate the mean difference in performance for each of these
permutations.
If the difference between actual on- and off-treatment means
is greater than that for any other combination, it is possible to
calculate how often this would happen by chance. In general,
the actual difference between means will be statistically signif-
icant at the 5% level, if this difference falls in the 5% most
extreme differences in the distribution of possible recombina-
tions of the data.14
In this case, the total number of permutations for our three
off- and ﬁve on-treatment observations is 56. Therefore, if the
difference between actual on- and off-treatment means is greater
than the mean difference for all the other possible recombina-
tions of the dataset, the probability of this occurring purely by
chance is 1/56¼0.018.
This analysis revealed that rightward deviation on line bisec-
tion reduced signiﬁcantly (ﬁgure 1B) after commencing guanfa-
cine (p¼0.018), demonstrating clear amelioration of the spatial
bias most characteristic of neglect. The number of items iden-
tiﬁed on line cancellation also increased (ﬁgure 1C), although
this did not reach statistical signiﬁcance (p¼0.071). On the other
hand, accurate target detection (perceptual sensitivity) over the
8 min computerised sustained attention task was signiﬁcantly
enhanced (p¼0.018, ﬁgure 1D), revealing that, in addition to
ameliorating aspects of the spatial bias of neglect, guanfacine
was able to improve the deﬁcit in sustained attention.
Clinical observation was consistent with these data, with the
patient’s general level of alertness and arousal improving
following introduction of guanfacine. Furthermore, after a period
of 6 months on the drug, his carers reported an ‘improvement in
his awareness and conversation.’ to the extent that he was able
to ‘.contribute signiﬁcantly to crossword puzzles and enjoy his
music CDs.’ As a result of these persistent beneﬁts, the patient
continues to take 2 mg guanfacine daily.
DISCUSSION
The case presented here demonstrated severe hemispatial neglect
and impairments in sustained attention, associated with bilat-
eral thalamic lesions caused by ADEM. Initiation of the norad-
renergic agonist guanfacine led to an improvement of these
deﬁcits, which persisted with continued guanfacine use. Thalamic
lesions, especially those involving the medial nucleidincluding the
medial pulvinardare most frequently associated with deﬁcits in
arousal, which can be particularly severe following bilateral
damage, as can occur following stroke.10 Hemispatial neglect is
also often reported, again following strokes involving the medial
thalamus and pulvinar, most frequently in the right
hemisphere.10 11 15 In contrast, these impairments have rarely
been referred to in the literature as a sequela of ADEM.3
Difﬁculty with arousal or maintaining alertness, so that
attention can be sustained on current goals, is increasingly
accepted as a component of the neglect syndrome, capable in
fact of predicting the severity of the spatial bias.16 It has been
proposed that arousal is dependent on noradrenergic input from
the locus coeruleus to inferior parietal and frontal cortex, and
indirectly to these regions via the thalamus.15 Damage to these
regions can also be associated with neglect.11e13
Further evidence of the intimate link between arousal and the
spatial orientation of attention comes from rehabilitation
studies. Alertness training can improve neglect,17 while single
doses of guanfacine have previously been shown to enhance
sustained attention, in addition to ameliorating the spatial
deﬁcit.6 Although continued guanfacine use has been demon-
strated to be efﬁcacious in the treatment of inattentiveness in
children and adolescents with attention-deﬁcit/hyperactivity
disorder,5 this is the ﬁrst demonstration of a persistent amelio-
ration of at least some components of the spatial deﬁcit of
neglect with a noradrenergic agonist.
Funding This research is supported by The Wellcome Trust and the NIHR CBRC at
UCLH/UCL.
Competing interests None.
Ethics approval Ethics approval was provided by the UCLH/UCL.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis:
a follow-up study of 40 adult patients. Neurology 2001;56:1313e18.
2. Bernarding J, Braun J, Koennecke HC. Diffusion- and perfusion-weighted MR
imaging in a patient with acute demyelinating encephalomyelitis (ADEM). J Magn
Reson Imaging 2002;15:96e100.
3. Sunnerhagen KS, Johansson K, Ekholm S. Rehabilitation problems after acute
disseminated encephalomyelitis: four cases. J Rehabil Med 2003;35:20e5.
4. Hollinger P, Sturzenegger M, Mathis J, et al. Acute disseminated encephalomyelitis
in adults: a reappraisal of clinical, CSF, EEG, and MRI findings. J Neurol
2002;249:320e9.
5. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-
controlled study of guanfacine extended release in children and adolescents with
attention-deficit/hyperactivity disorder. Pediatrics 2008;121:E73e84.
6. Malhotra PA, Parton AD, Greenwood R, et al. Noradrenergic modulation of space
exploration in visual neglect. Ann Neurol 2006;59:186e90.
7. Malhotra P, Coulthard EJ, Husain M. Role of right posterior parietal cortex in
maintaining attention to spatial locations over time. Brain 2009;132:645e60.
8. Stanislaw H, Todorov N. Calculation of signal detection theory measures. Behav
Res Meth Instrum Comput 1999;31:137e49.
9. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of
attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry
1995;34:50e4.
10. Schmahmann JD. Vascular syndromes of the thalamus. Stroke
2003;34:2264e78.
11. Karnath HO, Himmelbach M, Rorden C. The subcortical anatomy of human spatial
neglect: putamen, caudate nucleus and pulvinar. Brain 2002;125:350e60.
12. Mort DJ, Malhotra P, Mannan SK, et al. The anatomy of visual neglect. Brain
2003;126:1986e97.
13. Husain M, Kennard C. Visual neglect associated with frontal lobe infarction. J Neurol
1996;243:652e7.
14. Todman J. Randomisation in single-case experimental designs. Adv Clin Neurosci
Rehabil 2002;2:18e19.
15. Watson RT, Valenstein E, Heilman KM. Thalamic neglect. Possible role of the medial
thalamus and nucleus reticularis in behavior. Arch Neurol 1981;38:501e6.
16. Robertson IH, Manly T, Beschin N, et al. Auditory sustained attention is a marker of
unilateral spatial neglect. Neuropsychologia 1997;35:1527e32.
17. Sturm W, Thimm M, Kust J, et al. Alertness-training in neglect: behavioral and
imaging results. Restor Neurol Neurosci 2006;24:371e84.
690 J Neurol Neurosurg Psychiatry 2011;82:688e690. doi:10.1136/jnnp.2009.195792
Short report
